Precigen Faces Mounting Losses as Analysts Brace for Widening Deficit

Precigen Inc (PGEN) reports fourth-quarter 2025 earnings after market close on March 25, 2026. With analysts expecting losses to more than double year-over-year and technical indicators flashing warning signs, investors face a critical test of whether the biotechnology company can stabilize its financial trajectory or continue its descent into deeper red ink.

Part 1: Earnings Preview

Precigen Inc is a biopharmaceutical company focused on developing gene and cell therapies for cancer and infectious diseases. The company leverages its proprietary UltraCAR-T platform and AdenoVerse immunotherapy technology to advance clinical-stage programs targeting solid tumors and other therapeutic areas.

Analysts expect Precigen to report a loss of $0.09 per share for the fourth quarter of 2025, with estimates ranging from -$0.07 to -$0.12. The company most recently reported a loss of $0.11 per share for the third quarter of 2025. Compared to the same quarter last year, when Precigen posted a loss of $0.04 per share, the consensus estimate represents a 125% deterioration in earnings performance — a significant widening of losses that underscores mounting operational challenges.

Three key themes define this earnings story:

Clinical Pipeline Progress: Investors will scrutinize updates on Precigen's UltraCAR-T programs and AdenoVerse platform trials. Any advancement in clinical milestones or regulatory interactions could provide a counterweight to the deteriorating financial metrics and signal long-term value creation potential.

Cash Burn and Runway: With losses accelerating, the company's cash position and quarterly burn rate take center stage. Management commentary on funding needs, potential partnerships, or strategic alternatives will be critical for assessing whether Precigen can sustain operations through key clinical readouts.

Operational Efficiency Initiatives: As losses widen, investors need evidence that management is taking decisive action to control costs and prioritize high-value programs. Any restructuring announcements or portfolio rationalization could help restore confidence in the company's path to profitability.

Analyst sentiment has shifted notably, with the consensus moving from a more optimistic stance to a cautious posture. The recent downgrade from one analyst — reflected in the shift from 3 strong buys a month ago to 2 currently, and the addition of a hold rating — suggests growing concern about the company's near-term prospects and ability to meet development milestones.

Part 2: Historical Earnings Performance

Precigen has demonstrated a mixed but generally positive track record of exceeding analyst expectations, though the pattern shows recent deterioration. Over the past four quarters, the company beat estimates three times and missed once, with an average surprise of approximately 7% when excluding the most recent quarter.

The company delivered consecutive beats in the first three quarters: December 2024 (-$0.04 vs. -$0.06 expected, a 33% beat), March 2025 (-$0.07 vs. -$0.08, a 13% beat), and June 2025 (-$0.11 vs. -$0.14, a 21% beat). These results suggested improving cost management and operational execution.

However, the most recent quarter in September 2025 broke this positive streak with a significant miss: Precigen reported a loss of $0.11 per share against expectations of -$0.08, representing a 38% negative surprise. This disappointing result, combined with the fact that losses are now expected to widen substantially in the upcoming quarter, raises questions about whether the company's earlier beats reflected sustainable improvements or merely temporary cost deferrals. The deteriorating trend suggests investors should approach the upcoming release with heightened caution.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Precigen reports after market close, meaning Day 0 reflects anticipatory trading before results are known, while Day +1 captures the market's first full reaction to the actual earnings data.

Precigen exhibits highly volatile post-earnings price behavior, with Day +1 moves averaging 6.42% and ranging as wide as 13.17% — substantially above typical small-cap biotech volatility. The most dramatic example came in November 2025, when the stock surged 26% the day after reporting, despite a modest 4% decline on earnings day itself. This pattern suggests that initial market reactions are often reversed as investors digest the full implications of results and management commentary. The 7.41% average Day 0 range indicates significant intraday volatility even before results are released, reflecting uncertainty and active positioning by traders. Investors should prepare for substantial price swings in both directions, with the potential for sharp reversals between the close on earnings day and the following session.

Part 2.2: Options Market Expected Move

The options market is pricing a 20.64% expected move through the April 17 expiration — substantially higher than the 6.42% average Day +1 historical move but more in line with the 13.17% average Day +1 range. This elevated implied volatility suggests options traders are anticipating an outsized reaction, possibly reflecting heightened uncertainty around clinical updates, cash runway concerns, or the potential for strategic announcements that could dramatically reshape the company's outlook.

Part 3: What Analysts Are Saying

Analyst sentiment toward Precigen presents a divided outlook with a notable recent deterioration. The current consensus shows 2 Strong Buy ratings and 2 Hold ratings, with an average recommendation of 4.00 on a 5-point scale. This represents a meaningful shift from one month ago, when the stock had 2 Strong Buys, 1 Hold, and 1 Strong Sell rating (average 3.50), indicating that one analyst upgraded from Strong Sell to Hold while sentiment otherwise remained stable.

Despite the mixed ratings, analysts maintain substantial upside expectations in their price targets. The mean target of $8.50 implies 172% upside from the current price of $3.13, with estimates ranging from $8.00 to $9.00. This wide gap between current trading levels and analyst targets suggests that the bullish analysts see significant value in Precigen's pipeline and technology platforms, even as near-term financial performance deteriorates.

The recent upgrade from Strong Sell to Hold, combined with the absence of any Moderate Buy or Moderate Sell ratings, reflects a polarized view of the stock. The bulls appear to be betting on long-term clinical and commercial potential, while the more cautious analysts have moved to the sidelines rather than turning outright negative. This setup suggests that upcoming earnings could serve as a catalyst to either validate the bulls' conviction or prompt further downgrades if execution continues to disappoint.

Part 4: Technical Picture

Precigen enters earnings in a deteriorating technical position, with the Barchart Technical Opinion registering a 24% Sell signal — a significant weakening from the 48% Buy signal just one month ago. The rapid shift through an 8% Sell signal last week indicates accelerating negative momentum as the stock approaches its earnings release.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative, suggesting traders are positioning defensively ahead of earnings
• Medium-term (50% Buy): Moderate buy signal suggests some underlying support remains in the intermediate timeframe, creating a tension between short-term weakness and medium-term potential
• Long-term (50% Sell): Moderate sell signal reflects concern about the longer-term trend, consistent with widening losses and deteriorating fundamentals

Trend Characteristics: The weak but strengthening sell signal suggests the technical environment is becoming increasingly unfavorable, though the trend has not yet reached extreme oversold conditions that might indicate capitulation.

The stock is trading at $3.13, below all major moving averages: the 5-day ($3.25), 10-day ($3.35), 20-day ($3.46), 50-day ($4.11), 100-day ($4.08), and 200-day ($3.42). This universal resistance from moving averages confirms the downtrend and suggests the stock faces significant technical overhead. The 50-day and 100-day averages near $4.10 represent a critical resistance zone approximately 31% above current levels.

The 200-day moving average at $3.42 represents the nearest meaningful resistance level, just 9% above the current price. A strong earnings beat and positive guidance could propel the stock through this level, potentially triggering short covering and momentum buying. Conversely, the lack of any nearby support levels suggests that a disappointing report could accelerate the decline, with the next logical support zone likely in the $2.50-$2.75 range based on the historical Day +1 range of 13%. The technical setup is decidedly cautionary heading into this release, with the burden of proof squarely on management to deliver results that can reverse the negative momentum.